LC
EPZM

Lindbrook Capital’s Epizyme, Inc EPZM Stock Holding History

Lindbrook Capital’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-116
Closed -$1K – 2050
2021
Q2 		$1K Buy
+116
New +$978 ﹤0.01% 1886
2020
Q2 		– Sell
-60
Closed -$1K – 1937
2020
Q1 		$1K Buy
+60
New +$1.29K ﹤0.01% 1635

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KXA
KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lindbrook Capital's EPZM Position: Q3 2021 in Review

Lindbrook Capital sold out of Epizyme, Inc (EPZM) in Q3 2021, closing a stake of 116 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in EPZM in Q1 2020 and held it in 2 quarters. The position peaked at $1K in Q2 2021. 116 funds tracked by Wall St. Rank hold EPZM as of Q3 2021.

  • Lindbrook Capital reported no remaining Epizyme, Inc position as of Q3 2021 after selling out during the quarter.
  • Lindbrook Capital sold 116 Epizyme, Inc shares in Q3 2021, an estimated $1K.
  • Lindbrook Capital first reported a position in Epizyme, Inc in Q1 2020 and held it in 2 quarters.
  • Lindbrook Capital's Epizyme, Inc position peaked at $1K in Q2 2021.
  • 116 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2021.

Based on Lindbrook Capital's 13F filing for Q3 2021, filed 5 Nov 2021.